Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives Average Recommendation of “Buy” from Brokerages

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) has earned a consensus rating of “Buy” from the ten analysts that are covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell rating, seven have assigned a buy rating and two have assigned a strong buy rating to the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $20.89.

YMAB has been the subject of a number of research analyst reports. Wedbush reissued an “outperform” rating and issued a $23.00 price target on shares of Y-mAbs Therapeutics in a research report on Friday, January 10th. Oppenheimer assumed coverage on shares of Y-mAbs Therapeutics in a research note on Monday, November 18th. They set an “outperform” rating and a $23.00 target price for the company. Brookline Capital Management began coverage on shares of Y-mAbs Therapeutics in a research note on Thursday, December 5th. They issued a “buy” rating and a $17.00 price target on the stock. Finally, HC Wainwright reissued a “buy” rating and set a $22.00 price objective on shares of Y-mAbs Therapeutics in a research report on Monday, January 13th.

Institutional Trading of Y-mAbs Therapeutics

Large investors have recently made changes to their positions in the stock. Acorn Capital Advisors LLC bought a new position in shares of Y-mAbs Therapeutics in the 4th quarter valued at approximately $22,408,000. Caligan Partners LP raised its position in shares of Y-mAbs Therapeutics by 105.3% in the third quarter. Caligan Partners LP now owns 1,195,253 shares of the company’s stock valued at $15,718,000 after purchasing an additional 613,175 shares during the period. State Street Corp lifted its stake in shares of Y-mAbs Therapeutics by 50.4% in the third quarter. State Street Corp now owns 1,209,781 shares of the company’s stock worth $15,909,000 after buying an additional 405,169 shares during the last quarter. Infinitum Asset Management LLC bought a new stake in shares of Y-mAbs Therapeutics during the 4th quarter worth $1,218,000. Finally, Paradigm Biocapital Advisors LP boosted its holdings in shares of Y-mAbs Therapeutics by 3.7% during the 4th quarter. Paradigm Biocapital Advisors LP now owns 4,236,346 shares of the company’s stock worth $33,171,000 after buying an additional 150,000 shares during the period. Institutional investors own 70.85% of the company’s stock.

Y-mAbs Therapeutics Trading Up 2.5 %

Shares of YMAB stock opened at $5.56 on Friday. The company has a market capitalization of $248.85 million, a price-to-earnings ratio of -10.29 and a beta of 0.67. Y-mAbs Therapeutics has a 1-year low of $5.28 and a 1-year high of $20.90. The stock’s fifty day simple moving average is $6.64 and its 200-day simple moving average is $10.76.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.